First PREMIER Bank increased its stake in Amgen Inc. (NASDAQ:AMGN) by 5.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,742 shares of the medical research company’s stock after acquiring an additional 460 shares during the period. First PREMIER Bank’s holdings in Amgen were worth $1,506,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Jackson Grant Investment Advisers Inc. grew its position in Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after acquiring an additional 4 shares in the last quarter. M Holdings Securities Inc. grew its position in Amgen by 0.6% in the first quarter. M Holdings Securities Inc. now owns 2,825 shares of the medical research company’s stock worth $463,000 after acquiring an additional 18 shares in the last quarter. Kovitz Investment Group Partners LLC grew its position in Amgen by 1.2% in the first quarter. Kovitz Investment Group Partners LLC now owns 3,223 shares of the medical research company’s stock worth $529,000 after acquiring an additional 38 shares in the last quarter. Middleton & Co Inc MA grew its position in Amgen by 2.3% in the first quarter. Middleton & Co Inc MA now owns 1,780 shares of the medical research company’s stock worth $292,000 after acquiring an additional 40 shares in the last quarter. Finally, AMG Funds LLC grew its position in Amgen by 0.4% in the first quarter. AMG Funds LLC now owns 10,089 shares of the medical research company’s stock worth $1,655,000 after acquiring an additional 41 shares in the last quarter. Institutional investors own 78.14% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “First PREMIER Bank Buys 460 Shares of Amgen Inc. (AMGN)” was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/16/first-premier-bank-buys-460-shares-of-amgen-inc-amgn.html.

Several research analysts recently commented on the company. Royal Bank Of Canada assumed coverage on Amgen in a research report on Thursday. They issued a “sector perform” rating and a $192.00 price target for the company. BMO Capital Markets lowered Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, July 26th. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $203.00 price target (up previously from $189.00) on shares of Amgen in a research report on Wednesday, July 26th. Deutsche Bank AG reiterated a “hold” rating and issued a $174.00 price target (up previously from $172.00) on shares of Amgen in a research report on Wednesday, July 26th. Finally, Cann reiterated a “buy” rating and issued a $203.00 price target (up previously from $189.00) on shares of Amgen in a research report on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company. Amgen currently has an average rating of “Buy” and a consensus price target of $186.14.

Shares of Amgen Inc. (NASDAQ:AMGN) traded down 1.04% during trading on Friday, reaching $187.47. 5,348,992 shares of the company were exchanged. The firm has a 50-day moving average price of $175.31 and a 200-day moving average price of $169.32. The stock has a market capitalization of $136.79 billion, a P/E ratio of 17.08 and a beta of 1.35. Amgen Inc. has a 1-year low of $133.64 and a 1-year high of $191.10.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. The company had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the business earned $2.84 EPS. Equities research analysts predict that Amgen Inc. will post $12.57 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Thursday, August 17th were issued a dividend of $1.15 per share. The ex-dividend date of this dividend was Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a yield of 2.45%. Amgen’s dividend payout ratio (DPR) is presently 41.93%.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.